
Immunocore Holdings (IMCR) Stock Forecast & Price Target
Immunocore Holdings (IMCR) Analyst Ratings
Bulls say
Immunocore Holdings PLC has demonstrated a robust commercial trajectory for its lead product, KIMMTRAK, which has consistently outperformed quarterly sales expectations in 12 out of 14 quarters since its launch. The company is well-positioned for growth, with expectations of increased penetration in the US community setting and potential expansion into additional international markets, supported by a deep pipeline of assets across oncology, infectious, and autoimmune disease areas. Furthermore, the successful approval of KIMMTRAK by both the FDA and EMA in early 2022 underscores its market reliability, contributing positively to investor sentiment regarding the company's valuation.
Bears say
Immunocore Holdings PLC faces a negative outlook primarily due to disappointing data disclosures for key clinical programs, specifically revealing a low Overall Response Rate (ORR) of 11% for cutaneous melanoma and 6% for ovarian cancer, which fell short of market expectations. Additionally, the potential for significant market erosion is exacerbated by emerging competition from IDYA's darovasertib and combination therapies that could challenge KIMMTRAK's market position in the HLA-A2+ metastatic uveal melanoma segment. Finally, the company is susceptible to risks associated with R&D and regulatory delays, potential new competitors, and challenges related to financing, which could adversely affect its financial stability and growth trajectory.
This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.
Immunocore Holdings (IMCR) Analyst Forecast & Price Prediction
Start investing in Immunocore Holdings (IMCR)
Order type
Buy in
Order amount
Est. shares
0 shares